急性血栓性脳卒中におけるテネクテプラゼ: 韓国脳卒中学会からの科学的声明

Hyunsoo Kim¹, Joon-Tae Kim², Beom Joon Kim³

¹Department of Neurology, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea.

Journal of clinical neurology (Seoul, Korea)

|August 29, 2025

まとめ

テネクテプラス (TNK) は,急性性不全性脳卒中 (AIS) の治療に有望な代替薬です. この科学的な声明は,TNKの採用を支持し,患者の成果を改善することを目指しています.

科学分野:

神経学
心血管医学
薬理学について

背景:

テネクテプラス (TNK) は,急性不全性脳卒中 (AIS) の血栓解消剤として有望である.
韓国を含む多くの地域では,AISにおけるTNKの規制承認と払い戻しの方針が欠けている.
これはAIS患者にとって治療上のギャップを生み出します

研究の目的:

急性不全性脳卒中 (AIS) のためのテネクテプラス (TNK) に関する政策変更を報告する.
まだ利用できない地域でのTNKの導入を支援する.
AISの患者は,血栓解消療法における進歩の恩恵を受けられるようにするためです.

主な方法:

2010年1月から2024年11月までの間に発表されたランダム化制御試験 (RCT),メタ解析,および体系的なレビューのレビュー.
TNKの有効性と安全性に関する臨床的証拠を提供するRCTを独占的に評価するメタアナリシスを含みます.
国際専門家パネルによる声明の徹底的検討と最終化.

主要な成果:

AIS発症から4. 5時間以内にアルテプラスに対する有効な代替薬である.
TNK (0. 25 mg/ kg) と比較して,大血管閉塞のAIS患者で,血管内血栓切除が可能な臨床結果の改善が観察されました.

結論:

これらの記述は,TNKがまだ利用できない国々での採用を支持する最新の臨床的証拠を提供します.
これらの記述の実施は,AIS患者の治療選択肢を広げることができます.
TNKの採用は,急性脳卒中治療の慣行を国際基準に合わせるのに役立つかもしれません.

キーワード:

急性不全性脳卒中アルテプラス機能的な結果静脈内血栓解離テネクテプラス

さらに関連する動画

09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.1K

09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

2.9K

関連する概念動画

01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...

01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...

01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...

01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...

01:17

Ischemic Heart Disease: Overview

1.4K

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...

1.4K

01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...

関連する実験動画